| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $4,418 | 3 | 100 |
| Raday Gilead | Chief Operating Officer | 0 | $0 | 3 | $4,418 | $-4,418 |
RedHill Biopharma Ltd. is a specialized pharmaceutical firm concentrating its efforts mainly on therapies for digestive tract conditions and various infections. The company markets several gastrointestinal medications: Movantik, which addresses opioid-induced constipation in adults experiencing chronic non-cancer pain; Talicia, used to treat Helicobacter pylori infections in adult patients; and Aemcolo, prescribed for adults suffering from travelers' diarrhea. Its robust late-stage clinical pipeline features several promising investigational …
Over the last 12 months, insiders at RedHill Biopharma Ltd. have bought $0 and sold $4,418 worth of RedHill Biopharma Ltd. stock.
On average, over the past 5 years, insiders at RedHill Biopharma Ltd. have bought $0 and sold $4,418 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
| 2026-10-01 | Sale | Raday Gilead | Chief Operating Officer | 14.31M 0.1653% | $0.00 | $1,431 | +0.02% | |
| 2026-07-10 | Sale | Raday Gilead | Chief Operating Officer | 14.13M 0.0647% | $0.00 | $1,413 | -14.69% | |
| 2026-04-06 | Sale | Raday Gilead | Chief Operating Officer | 15.74M 0.0588% | $0.00 | $1,574 | -14.97% |
| Increased Positions | 7 | +46.67% | 475,973 | +2,018.12% |
| Decreased Positions | 4 | -26.67% | 82 | -0.35% |
| New Positions | 4 | New | 402,090 | New |
| Sold Out Positions | <1 | Sold Out | 17 | Sold Out |
| Total Postitions | 18 | +20% | 499,476 | +2,017.77% |